The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16–26 Years

Wheeler, Cosette M.; Kjær, Susanne K.; Sigurðsson, Kristján; Iversen, Ole‐Erik; Hernández-Ávila, Mauricio; Pérez, Gonzalo; Brown, Darron R.; Koutsky, Laura A.; Tay, Eng Hseon; García, Patricia J.; Ault, Kevin A.; Garland, Suzanne M.; Leodolter, Sepp; Olsson, Sven‐Eric; Tang, Grace; Ferris, Daron G.; Paavonen, Jorma; Steben, Marc; Bosch, F. Xavier; Dillner, Joakim; Joura, Elmar A.; Kurman, Robert J.; Majewski, Sławomir; Muñóz, Núbia; Myers, Evan R.; Villa, Luisa L.; Taddeo, Frank J.; Roberts, Christine C.; Tadesse, Amha; Bryan, Janine T.; Lupinacci, Lisa; Giacoletti, Katherine E.D.; James, Margaret K.; Vuocolo, Scott; Hesley, Teresa M.; Barr, Eliav

doi:10.1086/597309

Cited by 226 publications

(177 citation statements)

References 0 publications

Supporting

Mentioning

164

Contrasting

Unclassified

Order By: Relevance

“…38 Limited evidence is available to support the cross-protection by current vaccines against infection, persistence or cervical neoplasia caused by a few other HPV types (e.g., HPV31 and HPV45). [38][39][40][41] It is important to 56, 58 and 59), Group 2A (HPV68), Group 2B (HPV26, 53, 66, 67, 70, 73, 82) and Group 3 (HPV 6 and11). 3 Among IARC Group 1, the order of HPV types was judged by the best sensitivity, and best specificity in case of equal sensitivity, among histological CIS/cancer determine the role of HPV types in cervical cancer in Asia.…”

Section: Discussionmentioning

confidence: 99%

Prevalence of genotype‐specific human papillomavirus infection and cervical neoplasia in Taiwan: A community‐based survey of 10,602 women

Chen

You

Hsieh

et al. 2010

Intl Journal of Cancer

View full text Add to dashboard Cite

Human papillomavirus (HPV) causes cervical neoplasia; but limited data are available from Asia. We conducted a large‐scale community‐based cohort study in Taiwan to estimate prevalence of genotype‐specific HPV infection and cervical neoplasia. Following written informed consent, cervical cells for cytology and HPV testing were collected from 11,923 participants (aged 30–65 years old, mean 46.3) in 1991–1992. Genotyping was performed using MY11/GP6+ PCR‐based HPV Blot (EasyChip) for 39 HPV types. The overall HPV prevalence was 16.2% for 10,602 eligible participants, and 13.8% for 10,190 cytologically normal participants. The most common carcinogenic types were HPV52 (2.5%), HPV16 (2.0%), HPV56 (1.8%), HPV18 (1.6%), HPV33 (1.2%), HPV58 (1.3%) and HPV39 (1.0%). Among the 56 prevalent invasive and in situ cases, HPV16 (48.2%) was most common, followed by HPV58 (25.0%), HPV52 (19.6%), HPV31 (8.9%), HPV33 (8.9%) and HPV18 (3.6%). HPV16 and HPV58 caused cytological HSIL+ at younger ages than HPV52. Approximately half of the cervical cancer cases and high‐grade precursors in Taiwan could be prevented by prophylactic vaccines against HPV16 and HPV18 infection. Up to 40% more could be prevented by targeting HPV58, HPV52, HPV33 and HPV31, arguing for the introduction of vaccines including more types.

show abstract

Section: Discussionmentioning

confidence: 99%

Prevalence of genotype‐specific human papillomavirus infection and cervical neoplasia in Taiwan: A community‐based survey of 10,602 women

Chen

You

Hsieh

et al. 2010

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…10 proportion of high and low grade cervical lesions. 11 In two recent publications from the Gardisil FUTURE trials in 2009, Wheeler et al 12 and Brown et al 13 found there was significant crossprotection for these genotypes in terms of reduction against 6 mo persistent infection and precursor CIN 1-3 lesions, in particular, for HPV 31.…”

Section: Introductionmentioning

confidence: 99%

The effect of social determinants on immunization programs

Cremin

Menton²,

Canier³

et al. 2012

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…39 Because studies of both current HPV vaccines suggest only modest cross protection against some of these additional HPV types, [16][17][18] an increase in the type-specific protection of HPV vaccines from 70 to 90% would be highly desirable. The most simplistic approach to developing next-generation HPV vaccines is based on increasing the valency of the current vaccine formulations.…”

Section: Improvements In L1 Vlp Hpv Vaccinesmentioning

confidence: 99%

“…In addition, ethical considerations have already resulted in the systematic provision of HPV vaccines to untreated trial participants. 17,18 A new HPV vaccine could be evaluated in a randomised double-blind clinical trial using the licensed vaccine as a comparison group, with the intention of demonstrating equivalence or non-inferiority. Such trials, however, require large sample sizes and the use of endpoints less rare than CIN21.…”

Section: Endpoints For Evaluation Of Next-generation Vaccinesmentioning

confidence: 99%

“…16 In addition, recently the quadrivalent vaccine was shown to provide partial protection against CIN21 caused by a combination of highrisk types other than HPV16 and 18. 17,18 However, it remains unknown if partial cross-protection will be long-lasting or clinically relevant, especially in vast populations where the majority of cervical cancer pre-cancers and cancers are due to HPV 16 and 18. With respect to duration of vaccine efficacy, long-term community-based vaccine trials in Costa Rica 2 and the Nordic countries that will continue at least 9 years after vaccination will determine if booster doses are needed after the 3-dose primary series.…”

mentioning

confidence: 99%

See 1 more Smart Citation

EUROGIN 2008 roadmap on cervical cancer prevention

Franceschi

Cuzick

Herrero

et al. 2009

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

The EUROGIN 2008 Roadmap represents a continuing effort to provide updated information on primary and secondary prevention of cervical cancer. The report addresses several areas including the progress made toward global implementation of currently licensed human papillomavirus (HPV) vaccines, the possibilities and value of future-generation HPV vaccines, endpoints under consideration for evaluation of candidate HPV vaccines, and monitoring impact of HPV vaccination programmes that can be implemented within developed and less-developed countries. For the sake of completeness, a short update on the evolution of HPV testing in primary screening programmes at present and after HPV vaccine introduction has also been included. The report is available on the EUROGIN website (www.eurogin.com). ' UICCKey words: human papillomavirus; vaccine; screening; cervical cancer Update of new findings in 2008 and human papillomavirus vaccine implementationThe EUROGIN 2007 Roadmap on cervical cancer prevention was produced soon after the publication of decisive trials of quadrivalent and bivalent virus-like particle (VLP) human papillomavirus (HPV) vaccines (against HPV16, 18, 6 and 11 and HPV16 and 18, respectively). These included efficacy trials involving virological and precancerous cervical disease endpoints among women aged 15-26 years, and immunologic bridging trials with endpoints of safety and VLP serum antibody levels in female and male adolescents (reviewed in Schiller et al. 1 ). For both vaccines, efficacy against all considered endpoints associated with HPV vaccine types, including cervical intraepithelial neoplasia grade 2 or worse (CIN21), among young women who were not yet infected at the time of vaccination was greater than 95%.As expected, more limited protection was noted for both vaccines among women infected with HPV vaccine types before vaccination, and against endpoints associated with any HPV type. Neither vaccine was found to clear existing HPV infection 2 nor slow the rates of progression from infection to CIN. 3 These trials therefore demonstrated that both HPV vaccines are most effective when given to females na€ ıve to HPV vaccine types, i.e., prior to the onset of sexual activity.

show abstract

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16–26 Years

Abstract: ClinicalTrials.gov identifiers: NCT00092521 , NCT00092534 , and NCT00092482.

Cited by 226 publications

References 0 publications

Prevalence of genotype‐specific human papillomavirus infection and cervical neoplasia in Taiwan: A community‐based survey of 10,602 women

Prevalence of genotype‐specific human papillomavirus infection and cervical neoplasia in Taiwan: A community‐based survey of 10,602 women

The effect of social determinants on immunization programs

EUROGIN 2008 roadmap on cervical cancer prevention

Contact Info

Product

Resources

About